Klk26 Activators
Klk26 Activators consist of a collection of chemical compounds that indirectly stimulate the functional activity of Klk26, primarily through the inhibition of competing enzymes and the preservation of substrates. For instance, benzamidine, nafamostat, gabexate, and aprotinin all function as serine protease inhibitors, thereby reducing the activity of proteases that would otherwise deplete the substrates available to Klk26, thus enhancing its proteolytic capabilities. Similarly, leupeptin and phenylmethylsulfonyl fluoride (PMSF) act to limit the activity of a broad range of proteases, indirectly maintaining a greater reserve of peptide substrates for Klk26 action. AEBSF further contributes to this effect by specifically targeting serine proteases, while E-64, though primarily a cysteine protease inhibitor, may bolster Klk26 activity by lessening competition for shared substrates.
Additionally, compounds like tranexamic acid and camostat, by acting as antifibrinolytic and serine protease inhibitors respectively, ensure that Klk26 has an enhanced opportunity to interact with its specific substrates, promoting its enzymatic function. Aliskiren and valsartan, while not directly influencing Klk26, may modify systemic biological processes such as the renin-angiotensin-aldosterone system, thereby indirectly creatingconditions that could increase the activity of Klk26. Aliskiren's inhibition of renin and valsartan's blockade of angiotensin II receptors may lead to a series of physiological adjustments that favor the activation of pathways in which Klk26 is involved. Through these diverse yet interconnected mechanisms, these chemical activators collectively support the heightened functional activity of Klk26 by ensuring substrate availability and by possibly inducing favorable systemic changes conducive to its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nafamostat mesylate | 82956-11-4 | sc-201307 sc-201307A | 10 mg 50 mg | $82.00 $306.00 | 4 | |
Nafamostat, a synthetic serine protease inhibitor, can indirectly increase the activity of Klk26 by inhibiting competing serine proteases, thereby preventing substrate depletion and ensuring availability for Klk26-mediated catalysis. | ||||||
Gabexate mesylate | 56974-61-9 | sc-215066 | 5 mg | $100.00 | ||
As a serine protease inhibitor, gabexate can indirectly elevate Klk26 activity by preserving the peptide substrates that Klk26 acts upon, by reducing the activity of competing proteases. | ||||||
Aprotinin | 9087-70-1 | sc-3595 sc-3595A sc-3595B | 10 mg 100 mg 1 g | $112.00 $408.00 $3000.00 | 51 | |
Aprotinin is a potent inhibitor of plasma proteases. By inhibiting these proteases, aprotinin may allow Klk26 to have increased access to substrates, indirectly enhancing its proteolytic function. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin is an inhibitor of several proteases including serine proteases and can indirectly enhance Klk26's activity by reducing proteolytic competition, thereby increasing substrate availability for Klk26. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is an irreversible cysteine protease inhibitor. By inhibiting cysteine proteases, it could lead to an indirect increase in Klk26 activity due to less competition for substrates that both cysteine proteases and Klk26 might act upon. | ||||||
Phenylmethylsulfonyl Fluoride | 329-98-6 | sc-3597 sc-3597A | 1 g 100 g | $50.00 $697.00 | 92 | |
PMSF is a serine protease inhibitor that can indirectly enhance the activity of Klk26 by preventing degradation of its substrates by other serine proteases. | ||||||
AEBSF hydrochloride | 30827-99-7 | sc-202041 sc-202041A sc-202041B sc-202041C sc-202041D sc-202041E | 50 mg 100 mg 5 g 10 g 25 g 100 g | $65.00 $122.00 $428.00 $851.00 $1873.00 $4994.00 | 33 | |
AEBSF is a serine protease inhibitor that can indirectly increase the activity of Klk26 by reducing competition from other serine proteases. | ||||||
Tranexamic acid | 1197-18-8 | sc-204921 sc-204921A | 5 g 10 g | $29.00 $50.00 | 10 | |
Tranexamic acid is an antifibrinolytic that inhibits plasminogen activation. Its inhibition of plasmin can lead to increased substrate availability for Klk26, thereby indirectly enhancing its activity. | ||||||
Camostat mesylate | 59721-29-8 | sc-203867 sc-203867A sc-203867B sc-203867C sc-203867D sc-203867E | 10 mg 50 mg 500 mg 1 g 10 g 100 g | $43.00 $183.00 $312.00 $624.00 $2081.00 $4474.00 | 5 | |
Camostat is a serine protease inhibitor that can indirectly elevate Klk26's activity by reducing proteolytic competition, increasing the pool of substrates available for Klk26. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
Valsartan, an angiotensin II receptor blocker, may indirectly influence Klk26 activity by altering the renin-angiotensin system, potentially leading to changes in physiological conditions that could elevate the functional activity of Klk26. | ||||||